You just read:

Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

News provided by

Regeneron Pharmaceuticals, Inc.

Jun 11, 2017, 11:00 ET